Based on these knowledge, the role of Drp1 in the pathogenesis of several CVDs, including pulmonary arterial hypertension, HF, cardiac hypertrophy, IRI and myocardial infarction (MI), has been extensively addressed in the last years, highlighting the potentiality of this factor to effectively represent a strategy to treat CVDs [56]. This evidence concerns the gene DNM1L and cardiac hypertrophy.